Studies of plerixafor treatment on CXCR4 overexpressing NSCLC cell lines have demonstrated reduced cell migration, inhibited invasion, and enhanced apoptosis, especially in hypoxic conditions where CXCR4 expression is increased (Li C. et al., 2022). This evidence concerns the gene CXCR4 and non-small cell lung carcinoma.